The partnership will utilize ProSciento’s NASH Pass patient registry and Nordic Bioscience’s biomarker technology to identify and validate translational biomarkers to improve the diagnosis, prognosis, and development of therapeutics for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Read MoreThe researchers examined 1990–2017 data from the Global Burden of Disease Study pertaining to 195 countries and territories.
Read More
Daughters of women with polycystic ovarian syndrome are five times more likely to be diagnosed with the syndrome as adults, and the generational transmission is driven by high androgen levels during pregnancy.
Read More
The ELF test allows for identification of chronic liver disease in patients, including nonalcoholic fatty liver disease.
Read More
Study supports a potential technology antidote to difficult blood draws and failed IV starts.
Read More